Latest news about Sun Pharmaceutical
Sun Pharma Flags West Asia War Impact, Rising Logistics Costs; Withholds Margin Guidance
Sun Pharmaceutical Industries Records ₹39.99 Crore Block Trade on NSE at ₹1867.70 Per Share
Sun Pharmaceutical
1,796.50
-2.70(-0.15%)
Company Performance:
View Company Insights1D-0.15%
1M+1.00%
6M-1.92%
1Y+5.69%
5Y+168.82%
More news about Sun Pharmaceutical
21May 26
Sun Pharma May Face Increased Scrutiny Due To CDSCO's Action Against Cosmetic Injectables
Sun Pharma may face increased regulatory scrutiny following CDSCO's action against cosmetic injectables. The Central Drugs Standard Control Organisation's move signals heightened oversight in the cosmetic injectables segment. This development could have compliance implications for pharmaceutical companies, including Sun Pharma, active in this space. Market participants are closely monitoring the situation for further regulatory developments.
20May 26
Sun Pharma opens special window for physical share transfer
Sun Pharmaceutical Industries Limited announced a SEBI-mandated special window open from 05 February 2026 to 04 February 2027 for transferring physical shares bought before 01 April 2019. Transferred shares will be credited in demat mode and locked in for one year. Investors must submit specific documents to MUFG Intime India Private Limited to avail of this facility.
14May 26
Sun Pharmaceutical Receives Promoter Group Reclassification Requests Totalling 1.80% Shareholding
Sun Pharmaceutical Industries Limited disclosed on 14 May 2026 that it received requests from three Promoter Group members — Mr. Sudhir Vrundavandas Valia (1,43,45,019 shares; 0.60%), Mrs. Raksha Sudhir Valia (2,88,30,352 shares; 1.20%), and Mrs. Krishna Vrundavandas Valia — seeking reclassification to the 'Public' shareholder category under SEBI Listing Regulations. The combined disclosed shareholding of the applicants stands at 4,31,75,371 shares, representing 1.80% of total shares. The requests are subject to Board of Directors' approval and completion of the prescribed regulatory process before submission to stock exchanges.
14May 26
Sun Pharma Schedules Q4FY26 Results Announcement and Earnings Call for 22 May 2026
Sun Pharmaceutical Industries Limited has scheduled its Q4FY26 financial results announcement for 22 May 2026, alongside an hour-long earnings conference call at 06.30 pm IST. Senior management will discuss company performance and address investor queries. The announcement was filed with stock exchanges on 13 May 2026 by Company Secretary Anoop Deshpande.
13May 26
Sun Pharmaceutical Appoints Dr. Andreas Busch as Independent Director; Committee Reconstitution Also Approved
Sun Pharmaceutical Industries Limited's Board approved the appointment of Dr. Andreas Eugen Busch as an Independent Director for five consecutive years from 12 May 2026, pending shareholder approval. Dr. Busch, Chief Innovation Officer at Absci and Extraordinary Professor of Pharmacology at Johann Wolfgang Goethe-University, Frankfurt, has led R&D at Sanofi, Bayer, and Shire, resulting in over 15 FDA-approved commercial drugs. Separately, Ms. Satyavati Berera was appointed to the Audit Committee and Risk Management Committee effective 12 May 2026, ahead of Ms. Rama Bijapurkar's retirement on 20 May 2026.
09May 26
Sun Pharmaceutical Appoints Ms. Satyavati Berera as Independent Director Following Postal Ballot
Sun Pharmaceutical Industries Limited completed its postal ballot process on 08 May 2026, with shareholders approving the appointment of Ms. Satyavati Berera (DIN: 05002709) as an Independent Director for a five-year term. The postal ballot was initiated via a Notice dated 07 April 2026, with remote e-voting commencing on 09 April 2026. Voting results have been submitted to the stock exchanges, and the Scrutinizer's Report is available on the company's website.
07May 26
Sun Pharma Secures Court Order Barring United Biotech From Using 'Otide' Trademark
Sun Pharmaceutical has won a temporary court order barring United Biotech from using the brand name 'Otide', which the court found to be similar to Sun Pharma's trademark 'Octride'. The interim injunction was granted on the grounds that the resemblance between the two names could cause market confusion and harm Sun Pharma's brand reputation. The matter is expected to be further adjudicated, with the temporary protection remaining in place in the interim.
07May 26
Sun Pharma Signs Definitive Agreement to Acquire Organon & Company in $11.75 Billion Deal
Sun Pharmaceutical Industries Limited has announced a definitive agreement to acquire Organon & Company at $14 per share, implying an equity value of $3.99 billion and an enterprise value of $11.75 billion. The combined entity will have revenues of $12.4 billion, a presence in more than 150 markets, and a 24,000-strong commercial front-end team, with 18 markets each generating revenues exceeding $100 million. Management guided for cost synergies of $350 million over two to four years and confirmed the deal will be EPS accretive from the first full year of closing. The transaction is subject to Organon shareholder approval and customary regulatory clearances, with closing anticipated in approximately six to nine months.
29Apr 26
Sun Pharmaceutical Industries Executes ₹175.82 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a major block trade on NSE worth ₹175.82 crores involving 1,002,340 shares at ₹1754.10 per share. The transaction represents significant institutional activity and demonstrates strong liquidity in the pharmaceutical major's shares.
29Apr 26
Sun Pharmaceutical Industries Executes Rs. 195.59 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a major NSE block trade worth Rs. 195.59 crores involving 1,115,219 shares at Rs. 1753.80 per share. The transaction represents significant institutional activity in the pharmaceutical major's stock.
29Apr 26
Sun Pharmaceutical Industries Executes Rs. 28.06 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a Rs. 28.06 crore block trade on NSE involving approximately 159,853 shares at Rs. 1755.60 per share. The transaction represents significant institutional activity in the pharmaceutical sector, demonstrating efficient execution of large-volume trades outside regular market mechanisms.
29Apr 26
Sun Pharmaceutical Industries Executes Rs. 78.31 Crore Block Trade on NSE
Sun Pharmaceutical Industries Limited completed a major block trade on NSE worth Rs. 78.31 crores, involving approximately 445,511 shares at Rs. 1757.80 per share. This substantial institutional transaction demonstrates significant trading activity and continued market liquidity in the pharmaceutical company's shares.
28Apr 26
Sun Pharmaceutical Industries Executes Rs. 73.54 Crore Block Trade on NSE
Sun Pharmaceutical Industries executed a major block trade on NSE worth Rs. 73.54 crores, involving 419,696 shares at Rs. 1752.30 per share. This substantial institutional transaction reflects significant trading activity and investor interest in the pharmaceutical major's stock.
28Apr 26
Sun Pharmaceutical Industries Executes Rs. 43 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a major block trade on NSE worth Rs. 43.00 crores, involving approximately 247,723 shares at Rs. 1,736.00 per share. This significant institutional transaction highlights notable market activity in the pharmaceutical major's stock.
28Apr 26
Sun Pharma Signs $11.75B Organon Deal: Morgan Stanley Highlights Synergies
Sun Pharmaceutical Industries has signed a definitive $11.75 billion acquisition agreement for Organon & Co. at $14 per share, expected to close in early 2027. Morgan Stanley analysis highlights the deal's strategic value in building a global platform through diversification into women's health and biosimilars, with projected cost synergies of ~$350 million and EPS accretion from Year 1.
28Apr 26
Macquarie Maintains Outperform Rating on Sun Pharmaceutical Industries with ₹2,150 Target Price
Macquarie has maintained its Outperform rating on Sun Pharmaceutical Industries with a target price of ₹2,150. The brokerage believes current growth concerns are overdone and expects acquisition synergies to drive strong earnings accretion and provide significant upside for investors.
27Apr 26
Ademi LLP Investigates Organon Over Sun Pharmaceutical Transaction for Potential Legal Violations
Ademi LLP has launched an investigation into Organon & Co. for potential breaches of fiduciary duty and other legal violations in connection with a recently announced transaction involving Sun Pharmaceutical Industries. The legal inquiry focuses on examining whether Organon's conduct during the business arrangement may have violated obligations to stakeholders, though specific details about the transaction nature and alleged violations remain undisclosed.
27Apr 26
Sun Pharmaceutical Industries Executes Rs. 22.58 Crore NSE Block Trade
Sun Pharmaceutical Industries Ltd. completed a significant NSE block trade worth Rs. 22.58 crores, involving approximately 131,973 shares at Rs. 1711.00 per share. The transaction represents substantial institutional activity in the pharmaceutical sector and demonstrates the use of block trading mechanisms for large-volume executions.
25Apr 26
Sun Pharma Incorporates New USA Unit, Sun Pharma America
Sun Pharmaceutical Industries has established a new wholly-owned subsidiary, Sun Pharma America, Inc., in the United States on 23 April 2026. The incorporation is part of internal group structuring with cash consideration and was disclosed under SEBI Regulation 30 compliance on 24 April 2026.
21Apr 26
Sun Pharmaceutical Industries Executes Rs. 73.13 Crore NSE Block Trade
Sun Pharmaceutical Industries Limited completed a significant NSE block trade worth Rs. 73.13 crores, involving approximately 437,721 shares at Rs. 1670.60 per share. This substantial institutional transaction reflects active participation from large investors in the pharmaceutical company's stock through specialized trading mechanisms designed to handle high-volume trades efficiently.
19Apr 26
Sun Pharma Completes Postal Ballot Process with Shareholder Approval for Key Resolutions
Sun Pharmaceutical Industries Limited completed its postal ballot process on 17 April 2026, with shareholders approving three key resolutions including cost auditor remuneration ratification for FY 2025-26, MOA alteration, and Dr Pawan Goenka's re-appointment as Independent Director for five years from 21 May 2026. The company has filed voting results in XBRL mode and published the scrutinizer report on its website.
16Apr 26
Sun Pharma Faces Fresh Organon Acquisition Reports After Official Denial
New Bloomberg reports indicate Sun Pharma is reportedly looking to acquire debt-laden Organon, creating renewed market speculation after the company had officially denied earlier $12 billion acquisition rumors through regulatory filings to BSE and NSE in April 2026.
15Apr 26
Sun Pharmaceutical Industries Executes Rs. 61.23 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. executed a major NSE block trade worth Rs. 61.23 crores involving approximately 364,907 shares at Rs. 1,678.00 per share. The substantial transaction indicates significant institutional activity and demonstrates continued investor interest in the pharmaceutical major's stock.
08Apr 26
Sun Pharma Publishes Postal Ballot Newspaper Ads for Director Appointment
Sun Pharmaceutical Industries has published newspaper advertisements in Financial Express editions on April 8, 2026, containing postal ballot and e-voting information for Ms. Satyavati Berera's appointment as Independent Director. The e-voting process runs from March 19 to April 17, 2026, replacing the outgoing Woman Independent Director Ms. Rama Bijapurkar whose term expires on May 20, 2026.
01Apr 26
Sun Pharmaceutical Industries Executes ₹17.80 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a block trade worth ₹17.80 crores on NSE, involving approximately 101,082 shares at ₹1761.30 per share. The transaction represents significant institutional activity in the pharmaceutical stock, executed through NSE's block trading mechanism.
30Mar 26
High Court Restrains Intas From Selling Cancer Drug Similar To Sun Pharma's Bevetyx
The High Court has restrained Intas Pharmaceuticals from selling a cancer drug similar to Sun Pharma's Bevetyx. This legal victory protects Sun Pharma's intellectual property rights in the oncology segment and maintains the company's competitive advantage for its proprietary cancer treatment formulation.
28Mar 26
Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies
Sun Pharmaceutical Industries Limited received comprehensive clinical updates from partner Philogen showing mixed results across its drug pipeline. While Fibromun Phase II trials in soft tissue sarcoma (FLASH study) and glioblastoma (GLIOSTAR trial) did not meet primary endpoints, the company is advancing toward Phase III registrational studies including FIBROSARC-2. Nidlegy demonstrated stronger performance with 52.60% complete pathological responses in basal cell carcinoma patients and regulatory progress in both US and EU markets, with multiple registrational studies planned for the second quarter of 2026.
28Mar 26
Sun Pharma Presents 14 Research Abstracts at 2026 AAD Annual Meeting
Sun Pharmaceutical Industries Limited announced comprehensive research presentations at the 2026 AAD Annual Meeting with 14 abstracts covering three major therapeutic areas. The data includes Phase 3b results for ILUMYA showing sustained efficacy in nail psoriasis, breakthrough LEQSELVI results from THRIVE-AA trials demonstrating early scalp hair regrowth, and WINLEVI combination therapy studies showing progressive acne improvement, reinforcing the company's leadership in dermatology and immunology.
27Mar 26
Sun Pharmaceutical Industries Executes Rs. 25.04 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a significant NSE block trade worth Rs. 25.04 crores involving 139,124 shares at Rs. 1800.00 per share. The transaction represents substantial institutional activity and provides insights into large investor movements in the pharmaceutical sector.
27Mar 26
Sun Pharma Launches Semaglutide Injections as Jefferies Highlights Market Dynamics
Sun Pharmaceutical launched semaglutide injections under brand names Noveltreat for weight management and Sematrinity for diabetes treatment, priced competitively at ₹750-2,000 weekly therapy cost. Jefferies highlights favorable market dynamics post-Novo Nordisk patent expiry with 10+ current launches and 40+ expected, pricing range of ₹1,290-4,500, positioning Sun Pharma among leading scale players alongside Lupin and Torrent Pharma.
25Mar 26
UBS Maintains Buy Rating on Sun Pharmaceutical Industries, Cuts Target Price to Rs 2200
UBS maintains its Buy rating on Sun Pharmaceutical Industries while cutting the target price to Rs 2200 from Rs 2450. The brokerage highlights the company's rising specialty product mix led by Illumya, Leqselvi, and Unloxcyt, which supports growth and margin expansion. UBS also sees additional upside potential from a possible Semaglutide launch in India, which could further strengthen the specialty portfolio.
17Mar 26
Sun Pharmaceutical Industries Limited Announces Postal Ballot for Cost Auditor Ratification, MOA Amendment, and Director Re-appointment
Sun Pharmaceutical Industries Limited has announced a postal ballot process for three key resolutions: ratification of cost auditor remuneration of ₹31,26,000 for FY 2025-26, amendment to MOA for renewable energy activities, and re-appointment of Dr. Pawan Goenka as Independent Director for a second five-year term. The e-voting period runs from 19 March 2026 to 17 April 2026, with results expected by 20 April 2026.
17Mar 26
Sun Pharmaceutical Industries Limited Launches Shareholder Satisfaction Survey on RTA Services
Sun Pharmaceutical Industries Limited has launched a Shareholder Satisfaction Survey running from March 17-31, 2026, to collect feedback on RTA services provided by MUFG Intime India Private Limited. The survey targets shareholders who used RTA services between April 1, 2025, and December 31, 2025, with direct email communications being sent to eligible participants. The company aims to use this feedback to improve service efficiency, quality, and responsiveness as part of its commitment to strengthening shareholder relationships and services.
17Mar 26
Sun Pharma Secures FDA Acceptance for Ilumya Psoriatic Arthritis Treatment
Sun Pharmaceutical Industries has secured FDA acceptance for its supplemental biologics license application to expand Ilumya (tildrakizumab-asnm) treatment to adults with active psoriatic arthritis. The application is based on Phase 3 clinical studies and could position Ilumya as the only HCP-administered IL-23 biologic for this condition affecting 2.4 million Americans.
31Jan 26
Sun Pharma Reports Q3FY26 Revenue Growth to ₹155.2B; Earnings Call Recording Available
Sun Pharmaceutical Industries delivered robust Q3FY26 performance with consolidated revenue reaching ₹155.2 billion and net profit of ₹33.6 billion, representing growth of 13.5% and 16.0% respectively. The company maintained strong segment performance across India Formulations (16.2% growth), Emerging Markets (21.6% growth), and continued R&D investments. The Board approved an interim dividend of ₹11 per share with record date February 5, 2026, and made the earnings call audio recording available for stakeholder access.
28Jan 26
Sun Pharmaceutical Industries Executes ₹278.87 Crore Block Trade on NSE
Sun Pharmaceutical Industries Limited completed a major block trade on NSE worth ₹278.87 crores involving 1,734,892 shares at ₹1607.40 per share. The transaction represents significant institutional trading activity in the pharmaceutical major's equity.
27Jan 26
China Halts Sales of Sun Pharma's Dementia Drug Following Remote Inspection Issues
China has suspended sales of Sun Pharmaceutical's dementia drug after regulatory authorities identified issues during a remote inspection. The regulatory action represents a setback for the company's operations in the Chinese market, requiring resolution of the identified concerns before sales can resume.
23Jan 26
Sun Pharma Receives Approval for Generic Semaglutide Injection NovelTreat in India
Sun Pharmaceutical has obtained regulatory approval to manufacture and sell generic semaglutide injection for weight management in India under the brand name NovelTreat. The product will be available in five dose options and will launch after patent expiration, positioning the company to compete in the growing weight management pharmaceutical segment.
21Jan 26
Jefferies Maintains 'Buy' Rating on Sun Pharma with ₹2,100 Target Price
Jefferies has maintained its 'Buy' rating on Sun Pharmaceutical Industries with a target price of ₹2,100.00. The maintained recommendation reflects the global brokerage's continued positive assessment of the pharmaceutical company's investment prospects and business fundamentals. This rating provides investors with analyst guidance on the stock's potential performance and investment attractiveness.
20Jan 26
Sun Pharmaceutical Industries Schedules Board Meeting for Q3FY26 Results and Interim Dividend Consideration
Sun Pharmaceutical Industries Limited has scheduled a board meeting for January 31, 2026, to approve Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025, and consider interim dividend declaration. The record date for potential interim dividend distribution is set for February 5, 2026, with tax deduction at source applicable at prescribed rates. The company has implemented a trading window closure from January 1, 2026, until February 2, 2026, in compliance with regulatory requirements.
20Jan 26
Sun Pharmaceutical Industries Executes ₹20.56 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. completed a block trade worth ₹20.56 crores on NSE, involving approximately 125,250 shares at ₹1,641.20 per share. The transaction represents significant institutional activity in the pharmaceutical company's stock through the block trade mechanism.
19Jan 26
Sun Pharma Officially Denies $10 Billion Organon Acquisition Speculation
Sun Pharmaceutical Industries has officially denied media speculation regarding a potential $10 billion acquisition of US-based Organon through a formal BSE regulatory filing. The company stated the reports are speculative in nature with no material event requiring disclosure under Regulation 30, while reaffirming its commitment to maintaining highest governance standards and transparent communication with stakeholders.
19Jan 26
Sun Pharmaceutical Industries Denies $10 Billion Organon Acquisition Rumors
Sun Pharmaceutical Industries has officially denied rumors of a $10 billion acquisition of Organon, stating the information is speculative. The company clarified that no significant event requiring disclosure has occurred and emphasized its commitment to proper regulatory compliance and transparency with stakeholders.
16Jan 26
Sun Pharma Launches Unloxcyt™ for Advanced Cutaneous Squamous Cell Carcinoma Treatment
Sun Pharmaceutical has launched Unloxcyt™ (Cosibelimab-IPDL) for treating advanced cutaneous squamous cell carcinoma. This new oncology product expands the company's therapeutic portfolio and provides healthcare professionals with an additional treatment option for patients with this form of skin cancer, demonstrating Sun Pharma's continued commitment to addressing unmet medical needs in cancer care.
15Jan 26
Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer Treatment in US Market
Sun Pharma has successfully launched UNLOXCYT (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma treatment in the US market, achieving a significant milestone ahead of original timeline. The treatment shows strong clinical efficacy with 71% disease control rate and manageable safety profile, supported by the company's robust Q1 financial performance of ₹137,861 million gross sales and 10.1% year-over-year growth.
14Jan 26
LIC Increases Shareholding in Sun Pharmaceutical Industries to 5.004%
Life Insurance Corporation of India has increased its shareholding in Sun Pharmaceutical Industries Limited to 5.004% by acquiring 2,02,500 shares through market purchase on January 13, 2026. The acquisition took LIC's total holding to 12,00,79,148 shares from 11,98,76,648 shares, crossing the 5% threshold that requires mandatory disclosure under SEBI regulations. The disclosure was made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with Sun Pharmaceutical's total equity capital remaining unchanged at 2,39,93,34,970 shares.
28Dec 25
GLP-1 Obesity Treatment Drugs To Be New Growth Engine For Indian Pharma Industry: Sun Pharma MD
Sun Pharmaceutical's Managing Director Kirti Ganorkar identifies obesity and diabetes treatment drugs, particularly GLP-1 treatments, as a significant growth opportunity for India's pharmaceutical sector. The industry aims to transform from a generic drug manufacturing hub to a major player in the global weight management industry. Dr Reddy's Laboratories Chairman Satish Reddy emphasizes the need for accessible risk capital to elevate India's pharmaceutical industry to a global innovation hub. Icra projects 9-11% overall revenue growth for Indian pharmaceutical companies, with varying growth rates across different markets.
26Dec 25
Sun Pharma targets mid-high single digit revenue growth in FY26, focuses on R&D investments
Sun Pharmaceutical Industries targets mid to high single-digit consolidated revenue growth for FY26 while continuing R&D investments totaling ₹320 billion cumulatively. The company faces US policy challenges with proposed CMS pricing models that could impact its branded pharmaceuticals business. Strong Q2 performance showed net profit of ₹31.18 billion and revenue growth of 8.6% to ₹144.05 billion.
25Dec 25
Sun Pharma Unit Recalls Over 17,000 Units Of Antifungal Shampoo In US Due To Manufacturing Issues
Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical Industries, has recalled 17,664 units of Ciclopirox Shampoo in the United States. The recall, initiated on December 9, is due to failed impurity/degradation specifications. The FDA classified it as a Class II recall, indicating potential temporary or medically reversible health consequences. Ciclopirox Shampoo is used to treat seborrheic dermatitis, a skin condition causing dry, flaky, and itchy skin.
18Dec 25
Sun Pharma's Baska Facility Receives OAI Status After FDA Inspection
Sun Pharmaceutical Industries' Baska manufacturing facility has been classified as Official Action Indicated (OAI) following a US FDA inspection conducted from September 8-19. Despite this classification, the facility continues to manufacture and supply approved products to the US market. Sun Pharma has committed to working with the FDA to address the issues and achieve full compliance.
10Dec 25
Sun Pharma Strategically Limits Semaglutide Sales, Focuses on Patent-Free Markets
Sun Pharmaceutical Industries has adopted a cautious approach to semaglutide sales, exporting only to countries where Novo Nordisk lacks patents while suspending domestic sales until securing patent protection. This strategy reflects the company's commitment to legal compliance and intellectual property rights in the competitive pharmaceutical sector.
17Nov 25
AstraZeneca and Sun Pharma Join Forces to Expand Hyperkalemia Treatment in India
AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited have formed a strategic partnership to distribute Sodium Zirconium Cyclosilicate (SZC), an innovative Hyperkalemia treatment, across India. AstraZeneca will market the drug as Lokelma®, while Sun Pharma will use the brand name Gimliand®. The collaboration aims to leverage Sun Pharma's extensive distribution network to improve access to this crucial treatment for patients with chronic kidney disease and heart failure. Hyperkalemia affects up to 50% of CKD patients and 42% of chronic HF patients in India, with an associated mortality rate of 22.20%.
12Nov 25
Sun Pharma: Mixed Results for Fibromun Cancer Drug Trial and Positive Data for Obesity Drug Utreglutide
Sun Pharmaceutical Industries and Philogen S.p.A. announced mixed Phase III results for Fibromun in advanced soft tissue sarcoma. The FIBROSARC trial missed its primary endpoint but showed favorable trends in progression-free survival, objective response rate, and overall survival. Philogen plans to discuss results with regulators and initiate a new Phase III trial. Sun Pharma also presented positive clinical data for its obesity drug utreglutide (GLO034), demonstrating significant weight loss and metabolic improvements in multiple studies.
10Nov 25
Sun Pharma Reports Strong Q2 Performance with 8.6% Revenue Growth
Sun Pharmaceutical Industries posted robust Q2 FY24 results with revenue up 8.60% to ₹14,405.20 crore and net profit rising 2.60% to ₹3,118.00 crore. The global specialty business grew 16% YoY to $333 million, while domestic formulations revenue increased 11% to ₹4,734.80 crore. Operating profit rose 14.90% with margins expanding 170 bps to 31.30%. US generics faced challenges due to competition and declining Revlimid sales. R&D spending was ₹782.70 crore. The company plans to launch Unloxcyt for skin cancer in H2 FY26 and Leqselvi for alopecia areata, and enter the GLP-1 segment in India with Semaglutide.
05Nov 25
Sun Pharma Considers U.S. Manufacturing Expansion Amid Tariff Concerns and Strong Q2 Performance
Sun Pharmaceutical Industries is exploring expansion of its U.S. manufacturing operations following new tariffs on branded and patented medicines. The company reported robust Q2 results with sales of ₹144,052.00 million, up 8.60% YoY, and net profit of ₹31,180.00 million, up 2.60%. Global Innovative Medicines sales grew 16.40% to $333.00 million, surpassing Generics sales in the U.S. for the first time. Sun Pharma maintains its leading position in India with an 8.30% market share and continues to invest in R&D, with six novel entities in clinical stages.
05Nov 25
Sun Pharma Reports Robust Q2 Results with 8.86% Revenue Growth and Improved Profitability
Sun Pharmaceutical Industries Ltd announced its Q2 FY2026 financial results, showing robust performance. The company's consolidated revenue increased by 8.86% to ₹14,478.00 crore. Net profit rose by 2.57% to ₹3,118.00 crore. EBITDA grew by 14.90% to ₹4,527.00 crore, with the EBITDA margin expanding by 167 basis points to 31.27%. These results demonstrate Sun Pharma's strong market position, effective business strategies, and improved operational efficiency in the pharmaceutical industry.
04Nov 25
Sun Pharma Q2 Preview: Moderate Growth Expected Amid Specialty Business Expansion
Sun Pharmaceutical Industries Ltd is set to release its Q2 FY23-24 earnings report. Analysts project a 7% year-on-year revenue increase but only 2% growth in profit after tax due to higher expenses. The US market, including Taro Pharmaceuticals, faces challenges, while the global specialty business is expected to grow 14-15%. The Indian market is anticipated to show robust growth of 9-12%. R&D spending is estimated to increase to 6.50% of sales, and EBITDA margins are expected to face pressure due to increased spending on new drug launches.
23Oct 25
Sun Pharmaceutical Industries Sees Rs. 21.42 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved approximately 125,307 shares, valued at Rs. 21.42 crores, with a price per share of Rs. 1,709.50. This large-scale trade indicates substantial interest in Sun Pharma's shares and provides insight into the market's current valuation of the company.
22Oct 25
Sun Pharma Strengthens North American Leadership with New Corporate Affairs VP
Sun Pharmaceutical Industries Ltd. has appointed Jeremy Allen as the new Vice President of Corporate Affairs for North America. In this role, Allen will oversee corporate affairs initiatives including government relations, public policy, corporate communications, and stakeholder engagement. This strategic move aims to strengthen Sun Pharma's presence in the North American pharmaceutical market, enhance its ability to navigate regional regulatory environments, and improve stakeholder relations.
08Oct 25
NCLT Approves Sun Pharma's Merger with Subsidiaries, Enhancing Corporate Structure
Sun Pharmaceutical Industries Limited has obtained approval from the National Company Law Tribunal (NCLT) for a corporate restructuring plan. The approved Composite Scheme of Arrangement includes the merger of Sun Pharmaceutical Medicare Limited and four other wholly-owned subsidiaries with Sun Pharma. Additionally, the scheme involves reclassifying Sun Pharma's General Reserve to Retained Earnings. This merger is expected to simplify the company's corporate structure, potentially improving operational efficiency and streamlining decision-making processes.
26Sept 25
Sun Pharma Faces Potential Impact from Trump's 100% Tariff on Branded Drug Imports
US President Donald Trump announced a 100% tariff on branded and patented drugs imported into the United States, effective October 1. This could affect Sun Pharma's specialty product portfolio, which represents 19.30% of its overall sales. The tariffs include exemptions for companies with existing or under-construction US manufacturing plants. Sun Pharma's management suggests their current US manufacturing capacity is sufficient without additional investment. The company's specialty sales reached $1.20 billion, growing 17%, with Illumya sales increasing 17% to $681.00 million. Despite sector-wide concerns, Sun Pharma's stock closed unchanged at ₹1,625.00 and gained 1.50% over the past month.
18Sept 25
Suven Pharmaceuticals Witnesses Massive Block Trades Worth Rs. 3,278 Crores on NSE
Two significant block trades of Suven Pharmaceuticals shares occurred on the NSE during pre-open session, totaling approximately Rs. 3,278.00 crores. The first trade involved 8,712,631 shares worth Rs. 841.95 crores, while the second comprised 25,207,670 shares valued at Rs. 2,435.94 crores. Both trades were executed at Rs. 966.35 per share, involving a total of about 33.92 million shares.
09Sept 25
Sun Pharma's Halol Facility Hit by US FDA Import Alert, Impacting US Market Access
Sun Pharmaceutical Industries Limited's Halol facility has been classified as 'Official Action Indicated' by the U.S. FDA following an inspection from June 2 to June 13. The FDA has placed an import alert on the facility, restricting its ability to ship products to the United States due to non-compliance with current good manufacturing practices. Sun Pharma remains committed to addressing the compliance issues and working with the FDA to maintain CGMP standards at all its facilities.
08Sept 25
Sun Pharma Halts Production of Vecuronium Bromide Injection
Sun Pharmaceutical Industries Limited has stopped manufacturing Vecuronium Bromide Injection 20 MG, a neuromuscular blocking agent used in general anesthesia. The U.S. FDA has officially acknowledged this discontinuation. This decision may impact healthcare providers who regularly use this medication, potentially requiring them to seek alternative suppliers or consider other neuromuscular blocking agents. Sun Pharma has not provided specific reasons for the discontinuation or announced any plans to replace the product.
08Sept 25
Suven Pharmaceuticals Executes Rs. 76.37 Crore Block Trade on NSE
Sun Pharmaceutical Ltd. conducted a significant block trade on the National Stock Exchange (NSE), involving 819,263 shares at Rs. 932.15 per share, totaling Rs. 76.37 crores. This large-scale transaction indicates potential shifts in institutional holdings or strategic moves by major investors, potentially impacting the stock's liquidity and price dynamics in the short term.
05Sept 25
Sun Pharmaceutical Industries Sees Rs. 40.62 Crore Block Trade on NSE
Sun Pharmaceutical Industries Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 255,995 shares at Rs. 1,586.70 per share, totaling Rs. 40.62 crore. This large, privately negotiated trade outside regular trading systems may indicate institutional interest or shifts in major shareholding patterns.
01Sept 25
Sun Pharmaceutical Industries Executes Rs. 980 Crore Block Trade on NSE
Sun Pharmaceutical Industries executed a significant block trade on the National Stock Exchange (NSE). The transaction involved 6,227,856 shares traded at Rs. 1,573.60 per share, totaling Rs. 980.02 crores. This large-scale trade indicates potential institutional interest and may impact the company's shareholding patterns and stock liquidity.
04Aug 25
Sun Pharma Promoter Pledges Additional Shares for Third-Party Loan
Raksha Sudhir Valia, associated with Sun Pharmaceutical Industries Limited's promoter group, has pledged 650,000 additional equity shares to Citicorp Finance (India) Limited. This increases her total encumbered shareholding to 12,640,000 shares (0.53% of Sun Pharma's total share capital). The pledge, made on July 28, serves as security for a third-party loan. Valia's total shareholding in Sun Pharma stands at 28,830,352 shares (1.20% of total share capital).
01Aug 25
Sun Pharma Reports Strong Q1 Results Amid US Drug Pricing Pressure
Sun Pharmaceutical Industries Limited reported robust Q1 financial results with consolidated gross sales reaching ₹137,861.00 million, up 10.1% year-over-year. Adjusted net profit rose 5.7% to ₹29,961.00 million. India sales grew 13.9%, while US formulation sales increased 1.4%. The Global Innovative Medicines segment showed impressive 16.9% growth. However, the company faces challenges in the US market due to potential drug pricing pressures.
01Aug 25
Sun Pharma Reports Strong Q1 FY26 Performance with 10.1% Revenue Growth, Launches Leqselvi in US
Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with gross sales reaching ₹137,861.00 million, a 10.1% YoY increase. Adjusted net profit rose 5.7% to ₹29,961.00 million. India formulations sales grew 13.9%, US formulations by 1.4%, and Global Innovative Medicines business by 16.9%. The company launched Leqselvi in the US for severe alopecia areata. R&D investment was ₹9,029.00 million (6.5% of sales). A leadership transition was announced with Kirti Ganorkar set to become the new Managing Director.
01Aug 25
Sun Pharma Reports Strong Q1FY26 Results with 10.1% Revenue Growth
Sun Pharmaceutical Industries Limited reported robust financial results for Q1FY26. Gross sales reached ₹137,861.00 million, up 10.1% year-over-year. Adjusted net profit increased by 5.7% to ₹29,961.00 million, while EBITDA rose 19.2% to ₹43,017.00 million. The company showed strong performance across key markets, with India formulations growing 13.9%, US formulations up 1.4%, and Global Innovative Medicines segment growing 16.9%. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceutical market with an 8.3% market share. R&D investments stood at ₹9,029.00 million, representing 6.5% of sales. The company's pipeline includes 542 approved ANDAs and 119 pending approval in the US market.
31Jul 25
Sun Pharma Reports Strong Q1 FY26 Growth, Reaffirms U.S. Market Commitment
Sun Pharmaceutical Industries Limited reported robust Q1 FY26 results with consolidated gross sales reaching ₹137,861.00 million, a 10.1% year-over-year growth. Adjusted net profit rose by 5.7% to ₹29,961.00 million. EBITDA increased by 19.2% to ₹43,017.00 million. The company maintained leadership in the Indian market, increasing market share to 8.3%. R&D investments were ₹9,029.00 million, representing 6.5% of sales. Sun Pharma launched LEQSELVI in the U.S. market for severe alopecia areata treatment. The company clarified it has no immediate plans to expand manufacturing operations in the U.S.
31Jul 25
Sun Pharma Reports 10.1% Revenue Growth in Q1FY26, Board Approves Committee Restructuring
Sun Pharmaceutical Industries Limited reported robust Q1FY26 results with consolidated gross sales of Rs. 137,861.00 million, up 10.1%. Adjusted net profit increased by 5.7% to Rs. 29,961.00 million. The company maintained its leadership in the Indian market with a 13.9% growth in formulation sales. US formulation sales grew by 1.4%, while global innovative medicines sales increased by 16.9%. The company faced exceptional charges of Rs. 8,180.00 million and announced board restructuring. Sun Pharma also launched the dermatology drug LEQSELVI in the US market.
21Jul 25
Sun Pharma's Tildrakizumab Achieves Primary Endpoint in Phase 3 Psoriatic Arthritis Trials
Sun Pharmaceutical Industries Limited announced successful Phase 3 clinical trials for Tildrakizumab 100 mg (ILUMYA®) in treating active psoriatic arthritis. The INSPIRE-1 and INSPIRE-2 studies met their primary endpoint, showing statistically significant improvement in ACR20 response rates at Week 24 compared to placebo. The trials involved over 800 adult patients across the US, Europe, and Asia. The safety profile was consistent with ILUMYA's known profile, with no new safety signals. Sun Pharma plans to use these results for potential regulatory submissions in the US for ILUMYA in treating active psoriatic arthritis.
17Jul 25
Sun Pharma Expands into China with New Subsidiary
Sun Pharmaceutical Industries Limited has established a new subsidiary, Sun Pharma (Hainan) Company Limited, in China. The subsidiary, registered on July 16, 2025, aims to localize products, collaborate with Chinese partners for production, and conduct sales in the Chinese market. Sun Pharma will maintain 100% ownership of the subsidiary, either directly or through existing subsidiaries. This move provides direct access to the Chinese pharmaceutical market, potentially reducing costs and improving regulatory compliance.
15Jul 25
Sun Pharma Launches LEQSELVI™ in US for Severe Alopecia Areata and Settles Litigation with Incyte
Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) in the United States for treating adults with severe alopecia areata. The company also reached a settlement with Incyte Corporation, resolving litigation related to LEQSELVI™. The agreement includes a limited, non-exclusive license for Sun Pharma and involves upfront and ongoing royalty payments to Incyte. LEQSELVI™, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with some patients achieving 80% scalp coverage in as fast as 8 weeks. Sun Pharma has introduced a patient support program offering eligible patients medication for as little as $0 for up to two years.
14Jul 25
Sun Pharma Launches LEQSELVI™ for Severe Alopecia Areata in US, Settles Patent Dispute with Incyte
Sun Pharmaceutical Industries Limited has launched LEQSELVI™ (deuruxolitinib) 8 mg tablets in the US for treating severe alopecia areata in adults. The drug showed rapid results in clinical trials, with some patients achieving significant hair regrowth in as little as 8 weeks. Sun Pharma also announced a settlement with Incyte Corporation regarding LEQSELVI™ litigation, including a limited, non-exclusive license for certain US patents. The company will pay Incyte an upfront amount and ongoing royalties. These developments are expected to strengthen Sun Pharma's position in the US pharmaceutical market, particularly in dermatology.
14Jul 25
Sun Pharma Launches Leqselvi for Severe Alopecia Areata Treatment in U.S.
Sun Pharmaceutical Industries Limited has launched LEQSELVI (deuruxolitinib) in the United States for treating severe alopecia areata in adults. LEQSELVI, an oral JAK1 and JAK2 inhibitor, showed significant efficacy in clinical trials, with one-third of patients regaining almost all hair by Week 24. The drug addresses a condition affecting up to 2.50% of the U.S. and global population. Sun Pharma has introduced the LEQSELVI SUPPORT Program to enhance patient access, offering eligible individuals medication for as little as $0 for up to two years. The company has also reached a settlement with Incyte Corporation regarding patent-related litigation.
14Jul 25
Sun Pharma Reaches Settlement with Incyte Corporation in LEQSELVI™ Litigation
Sun Pharmaceutical Industries Limited has reached a settlement and license agreement with Incyte Corporation regarding the litigation over LEQSELVI™ (deuruxolitinib). The settlement includes dismissal of pending litigation, mutual release of claims, and Incyte granting Sun Pharma a limited, non-exclusive license for oral deuruxolitinib in specific non-hematology-oncology indications, including alopecia areata, in the United States. Sun Pharma will pay Incyte an upfront amount and ongoing royalties until patent expiry. This resolution allows Sun Pharma to potentially expand its presence in the U.S. market for certain deuruxolitinib indications.
25Jun 25
Sun Pharma's Partner Withdraws Skin Cancer Treatment Application in Europe
Sun Pharmaceutical Industries Ltd's partner, Philogen S.P.A., has withdrawn the marketing authorization application for their jointly developed skin cancer drug, Nidlegy™, from the European Medicines Agency (EMA). The withdrawal is due to timing issues with data availability. Philogen intends to resubmit an updated application in the future, indicating ongoing commitment to the drug's development. This temporary setback may delay potential revenue from Nidlegy™ in Europe and require additional studies or data before resubmission.
16Jun 25
Sun Pharma's Halol Facility Faces FDA Scrutiny: 8 Observations Issued
Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat underwent a U.S. FDA inspection from June 2 to June 13, resulting in a Form-483 with eight observations. The Form-483 indicates potential violations of the Food Drug and Cosmetic Act, though it's not a final determination of compliance. Sun Pharma must respond with a corrective action plan. The Halol facility has faced previous regulatory challenges, making this inspection significant for the company's U.S. business prospects. The company's response and ability to address these observations will be crucial for maintaining its position in the U.S. market.
16Jun 25
Sun Pharma's Halol Facility Receives FDA Form 483 with 8 Observations Following GMP Inspection
Sun Pharmaceutical's Halol facility has received a Form 483 from the US FDA, citing 8 observations following a GMP inspection. This comes after a previous warning letter and import alert for the same facility. The Halol plant remains under import alert since its last inspection in May 2022. Sun Pharma is expected to respond with a detailed corrective action plan to address the observations and work towards resolving the ongoing regulatory issues.
14Jun 25
FDA Inspection at Sun Pharma's Halol Plant Yields 8 Observations, Facility Remains Under Import Alert
Sun Pharmaceutical Industries Ltd's Halol facility in Gujarat has received a Form 483 from the US FDA following a GMP inspection from June 2-13. The form outlines eight observations, indicating potential GMP compliance issues. This development is significant as the facility is already under import alert due to a previous warning letter. Sun Pharma is expected to review and address these observations to ensure compliance with FDA standards. The Halol facility is crucial for Sun Pharma's US market supply, making resolution of these regulatory issues essential for the company's operations.
13Jun 25
Sun Pharma Announces Leadership Transition: Kirti Ganorkar Named New Managing Director, Dilip Shanghvi to Become Executive Chairman
Sun Pharmaceutical Industries Ltd has announced the appointment of Kirti Ganorkar as its new Managing Director, effective September 1, 2025, subject to shareholder approval. Ganorkar, who has been with the company since 1996, will oversee all business operations. Concurrently, founder Dilip Shanghvi will transition to the role of Executive Chairman of the Board. This leadership change aims to bring fresh perspectives while retaining experienced guidance in the company's strategic direction.
04Jun 25
Sun Pharma's SCD-044 Phase 2 Trial Falls Short of Primary Endpoint
Sun Pharmaceutical Industries Ltd announced that its Phase 2 clinical trial for SCD-044, a potential new medication, did not achieve its primary endpoint. This setback in the drug development process may impact the company's research and development outlook. Sun Pharma has not provided detailed information about next steps, but typical responses include reassessing the drug's potential, exploring alternative indications, or considering modifications to the compound.
03Jun 25
Sun Pharma Discontinues SCD-044 Drug After Failed Trials in Psoriasis and Atopic Dermatitis
Sun Pharmaceutical Industries Ltd has announced the discontinuation of its experimental drug SCD-044 following unsuccessful Phase 2 clinical trials for psoriasis and atopic dermatitis. The drug failed to meet the primary endpoint of 75% symptom improvement in both trials, involving 263 psoriasis patients and 250 atopic dermatitis patients. This represents a significant setback for Sun Pharma's research and development pipeline, leading to the decision to halt further development of SCD-044.
02Jun 25
Sun Pharma Projects Growth on New Launches Amid Profitability Challenges
Sun Pharmaceutical Industries expects mid-to-high single-digit revenue growth in FY26, driven by new product launches including Leqselvi and Unloxcyt. However, increased marketing expenses for specialty products and higher tax obligations may impact profitability. The company plans to invest 6-8% of sales in R&D. Despite a 19% decline in Q4 FY25 net profit due to higher taxes, revenue grew by 8% in the same quarter.
01Jun 25
Sun Pharma Unveils $100 Million Investment Plan for Specialty Products in FY26
Sun Pharmaceutical Industries plans to invest $100 million in FY26 to commercialize new specialty products, focusing on Unloxcyt and Leqselvi. The company aims for mid-to-high single-digit consolidated topline growth and will allocate 6-8% of sales to R&D. Sun Pharma is acquiring Checkpoint Therapeutics and seeking a partner for MM-II development. These strategic moves are aimed at strengthening its product pipeline and market position in the specialty pharmaceutical sector.
30May 25
Sun Pharma Completes Acquisition of Checkpoint Therapeutics
Sun Pharmaceutical Industries Ltd has successfully acquired Checkpoint Therapeutics, a company focused on developing cancer treatments. This strategic move is expected to expand Sun Pharma's oncology portfolio, enhance its R&D capabilities, and strengthen its position in the global pharmaceutical market. The acquisition could lead to synergies in research, development, and commercialization of cancer treatments. Specific financial details of the deal were not disclosed.
24May 25
Sun Pharma Sets Sights on Mid-to-High Single-Digit Revenue Growth for FY26
Sun Pharmaceutical Industries Ltd has announced its revenue growth target for fiscal year 2026, aiming for a mid-to-high single-digit increase. This projection factors in potential regulatory uncertainties in the crucial U.S. market. The company's strategy suggests a focus on sustainable expansion through diversification, innovation, market expansion, and operational efficiency. This cautious yet optimistic outlook reflects Sun Pharma's pragmatic approach to growth amid complex global pharmaceutical regulations.
23May 25
Sun Pharma Invests $25 Million in Pharmazz Inc, Increasing Stake to 22.7%
Sun Pharmaceutical Industries Ltd has agreed to invest up to $25 million in Pharmazz Inc, increasing its stake to 22.7%. The investment supports the development of two advanced drug candidates for stroke and shock. Sun Pharma gains options for licensing rights in certain markets, aligning with its strategy to expand its portfolio and market presence in specialty areas.
23May 25
Sun Pharma Q4 Profit Dips, Revenue Rises; Announces Dividend
Sun Pharmaceutical Industries Ltd reported mixed Q4 results. Net profit decreased to ₹21.50 billion from ₹26.50 billion year-over-year, falling short of market expectations. Revenue increased to ₹129.59 billion from ₹119.80 billion. The company reported an exceptional item of ₹3.62 billion and improved profit before tax of ₹36.20 billion. The board recommended a final dividend of ₹5.50 per equity share.
21May 25
Sun Pharma Q4 Preview: Revenue Growth Expected at 12.9%, Driven by gRevlimid Sales
Sun Pharmaceutical Industries Ltd is set to announce its Q4 results on Thursday. Analysts project a 12.9% YoY revenue increase to Rs 13,254.38 crore, driven by gRevlimid sales. Net profit is expected to rise 5.24% YoY to Rs 2,793.94 crore. US market revenues are anticipated to grow 10% YoY, with healthy growth in India and emerging markets. Investors will focus on R&D guidance, acquisition updates, and plant resolution progress.
20May 25
Sun Pharma Acquires Checkpoint Therapeutics for $616 Million, Bolstering Dermatology-Oncology Portfolio
Sun Pharmaceutical Industries has acquired Checkpoint Therapeutics for $616 million, including a $355 million upfront payment, $60 million contingent payment, and additional royalties. The acquisition, aimed at strengthening Sun Pharma's dermatology-oncology market position, brings key asset Unloxcyt to their portfolio. Macquarie views the deal as value accretive and has raised Sun Pharma's target price to Rs 2,135.00.
19May 25
Sun Pharma's BLU-U Device Upgrade Receives FDA Approval for Skin Treatment
Sun Pharmaceutical Industries has received FDA approval for an upgraded version of its BLU-U Blue Light Photodynamic Therapy device. The new model transitions from fluorescent tubes to LED technology, offering improved efficiency and usability in treating actinic keratosis, a pre-cancerous skin condition. This approval marks a significant advancement in Sun Pharma's medical device portfolio and reinforces its position in dermatological treatments.
Industry PeersSun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,796.50
(-0.15%)
6,553.50
(-1.70%)
4,350.40
(-1.37%)
1,390.30
(-0.76%)
1,091.20
(+1.25%)
1,290.40
(-1.00%)
2,262.90
(-0.21%)
2,320.20
(-2.33%)
1,433.70
(+0.51%)
1,388.40
(+1.94%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
